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Abstract
Advanced liver cirrhosis is usually accompanied by portal 
hypertension. Long-term portal hypertension results in 
various vascular alterations. The systemic hemodynamic 
state in patients with cirrhosis is termed a hyperdynamic 
state. This peculiar hemodynamic state is characterized 
by an expanded blood volume, high cardiac output, 
and low total peripheral resistance. Vascular alterations 
do not disappear even long after liver transplantation 
(LT), and recipients with cirrhosis exhibit a persistent 
systemic hyperdynamic state even after LT. Stability 
of optimal systemic hemodynamics is indispensable 
for adequate portal venous flow (PVF) and success-
ful LT, and reliable parameters for optimal systemic 
hemodynamics and adequate PVF are required. Even a 
subtle disorder in systemic hemodynamics is precisely 
indicated by the balance between cardiac output and 
blood volume. The indocyanine green (ICG) kinetics reflect 
the patient’s functional hepatocytes and effective PVF, 
and PVF is a major determinant of the ICG elimination 
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constant (k ICG) in the well-preserved allograft. The 
k ICG value is useful to set the optimal PVF during 
living-donor LT and to evaluate adequate PVF after LT. 
Perioperative management has a large influence on 
the postoperative course and outcome; therefore, key 
points and unexpected pitfalls for intensive management 
are herein summarized. Transplant physicians should 
fully understand the peculiar systemic hemodynamic 
behavior in LT recipients with cirrhosis and recognize 
the critical importance of PVF after LT.
Key words: Liver cirrhosis; Portal hypertension; Liver 
transplantation; Indocyanine green; Hyperdynamic
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: In patients with advanced cirrhosis who un-
dergo liver transplantation (LT), perioperative mana-
gement greatly influences the postoperative course and 
outcome. This review covers key points and unexpected 
pitfalls of intensive management in these patients. A 
peculiar systemic hemodynamic state (hyperdynamic 
state) persists in recipients with cirrhosis even after 
LT, and stability of optimal systemic hemodynamics is 
important for adequate portal venous flow (PVF) and 
successful LT. Reliable parameters for optimal systemic 
hemodynamics (a balance between cardiac output 
and blood volume) and adequate PVF (indocyanine 
clearance) during and after LT are herein described. 
Transplant physicians should fully understand these 
peculiar hemodynamic phenomena.
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INTRODUCTION
Advanced liver cirrhosis (LC) is usually accompanied 
by portal hypertension (PH). Long-term PH results in 
various vascular alterations, such as venous dilatation, 
endothelial damage, collateral pathway formation, and 
shunt development[1-3]. Some pathognomonic findings 
(e.g., varices, splanchnic congestion, intractable ascites, 
hepatic encephalopathy, and hepatorenal syndrome) are 
directly related to PH[3,4], and the pathophysiology of PH 
involves a complex of humoral and neural mechanisms[3]. 
These mechanisms determine hemodynamic changes 
and lead to a peculiar systemic circulation pattern[3]. 
The clinical implications of these peculiar systemic hemo-
dynamics in patients with LC have been described 
as a hyperdynamic state (so-called “hyperdynamic 
syndrome”)[3]. Specific manifestations that have been 
described include high cardiac output (CO), a large 
blood volume (BV), low total peripheral resistance (TPR), 
hyponatremic electrolyte abnormalities, and a lower 
potassium level due to secondary aldosteronism[5].
Here, we reviewed the peculiar systemic hemo-
dynamics in patients with advanced LC. We focused 
particularly on the systemic hemodynamic phenomena in 
liver transplantation (LT) recipients with LC because such 
LT recipients usually have long-term PH due to advanced 
LC. Adequate portal venous flow (PVF) to acquire satis-
factory graft function is attributed to continuous optimal 
systemic hemodynamic stability beginning immediately 
after LT[1,2]. Therefore, we herein review the optimal state 
of the systemic hemodynamics after LT for excellent 
outcomes and discuss key points and unexpected pitfalls 
in the perioperative intensive managements of recipients 
with LC. We also demonstrate the usefulness of indo-
cyanine green (ICG) during and after LT to estimate 
optimal systemic hemodynamics and adequate PVF.
SYSTEMIC HEMODYNAMICS IN 
PATIENTS WITH ADVANCED LC
The systemic hemodynamic state in patients with LC 
has been characterized as hyperdynamic[3,6,7]. Cirrhotic 
hemodynamics are characterized as hyperdynamic by 
a high CO, large BV, low TPR, mildly tachycardic heart 
rate (HR), and low or normal mean arterial pressure 
(MAP)[1-4,6,8-10]. Parameters of peripheral resistance, such 
as TPR, clearly reflect various vascular alterations[1-3,9,11,12].
NONINVASIVE METHODOLOGY FOR 
REAL-TIME ASSESSMENT OF SYSTEMIC 
HEMODYNAMIC STATE 
The ICG dye dilution curve can be used to measure 
hemodynamic parameters[13,14]. The currently available 
noninvasive method for measuring systemic hemo-
dynamic parameters is pulse dye densitometry (PDD). 
Its basic principles have been described in detail else-
where[13-16]. This noninvasive method is more reliable 
than invasive methods[13-15] and is suitable for clinical 
use because of its simplicity for bedside use, real-time 
presentation of results, and cost-effectiveness[15-17]. 
The principles of BV measurement using radioactive 
isotopes have already been established[18-20]. However, 
these techniques are associated with potential biohazards 
due to the use of radioactive indicators and require 
complex management. Indeed, these invasive methods 
using radioactive isotopes are completely unsuitable 
for BV monitoring during the perioperative period[14,15]. 
BV measurement by noninvasive PDD is considerably 
correlated with BV measurement by radioactive isotope 
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methods[21-23]; it is thus advantageous for real-time 
evaluation of BV[1,15]. 
SYSTEMIC HEMODYNAMIC BEHAVIOR 
AFTER LT
Adult LT recipients often develop peculiar hemodynamics 
due to advanced LC[1,2] (Figure 1). Mainly in the 1990s, 
various researchers focused on systemic hemodynamics 
after LT[8,9,11,12,24-28]. Controversial opinions exist regarding 
these systemic hemodynamic behaviors after LT. While 
several investigators found persistence of hyperdyna-
mic state[8,11,24-26], others insisted on a decrease toward 
normal ranges[12,27,28]. This discrepancy is believed to be 
due to the peculiarity of cirrhotic hemodynamics[9,11].
According to studies of TPR in recipients with LC, 
vascular alterations including venous dilatation and the 
development of collateral vessels and shunts do not 
disappear within the first month after LT[1,2]. These 
vascular alterations remain on imaging studies even 
several years after LT[29,30]. Various alterations in syste-
mic hemodynamics in recipients with LC should be 
maintained despite restoration of the liver function and 
portal venous pressure (PVP) after LT[8,11,24-26], and most 
systemic parameters are very slowly restored to the 
normal range after LT[9,11] (Figure 2). 
ACTUAL CHANGES IN SYSTEMIC 
AND SPLANCHNIC HEMODYNAMIC 
PARAMETERS AFTER LT
Hemodynamic and splanchnic systemic parameters 
were analyzed in 35 adult recipients who underwent 
living-donor LT (LDLT). All patients had advanced LC 
based on imaging studies and histopathological assess-
ments. ABO blood groups were identical or compatible. 
Combinations of lymphoid cross-matches were all negative. 
The CO, CI, BV, central blood volume (CBV), and HR 
were measured with a PDD apparatus. The TPR was 
measured simultaneously with the PDD examination; 
calculation of the TPR has been described in detail 
elsewhere[2,9]. Splanchnic circulatory parameters were 
simultaneously assessed using Doppler ultrasound. 
Measurements of splanchnic parameters including PVF 
has been described in detail elsewhere[2]. Measurements 
were performed before LDLT and from 1 to 14 d after 
LDLT. Measurements were repeated every 12 h until 
72 h after LDLT. To establish the normal ranges of each 
parameter, the variables were investigated in 16 healthy 
individuals (live donors before LDLT). Our 35 recipients 
were retrospectively classified into 2 groups based on 


























Figure 1  Vascular alterations in advanced liver cirrhosis. Collaterals 
along the round ligament are removed with native liver (red line). Collaterals 
developed around the native liver are also ligated (red line). AV: Azygos vein; 
GCT: Gastro-colic trunk; GCV: Gastric coronary vein; HAV: Hemi-azygos vein; 
IMV: Inferior mesenteric vein; IVC: Inferior vena cava; LCV: Left colic vein; LRV: 
Left renal vein; PV: Portal vein; SMV: Superior mesenteric vein; SPV: Splenic 















Figure 2  Intentional modulation of portal venous pressure during living-
donor liver transplantation. Splenectomy is chosen to reduce PVP (red dotted 
line). Ligations (red lines) of vessels (GCV, IMV, and GCT), collaterals (along 
LCV and around the native liver) and shunt (SRS) prevent a steal of PVF, and 
thereafter, PVF will increase (yellow arrow). AV: Azygos vein; GCT: Gastro-
colic trunk; GCV: Gastric coronary vein; HAV: Hemi-azygos vein; IMV: Inferior 
mesenteric vein; IVC: Inferior vena cava; LCV: Left colic vein; LRV: Left renal 
vein; PV: Portal vein; SMV: Superior mesenteric vein; SPV: Splenic vein; SRS: 
Splenorenal shunt; SVC: Superior vena cava.
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Twenty-seven recipients had good clinical courses after 
LDLT, although eight recipients developed graft failure. 
No significant differences were found in the Child-Pugh 
score (Figure 3A), graft-to-recipient weight ratio (GRWR), 
operative time, or intraoperative blood loss between 
the two groups; however, significant differences were 
found in the Model for End-Stage Liver Disease score 
(Figure 3B), duration of intensive care unit al) stay (Figure 
3C), and survival rate (Figure 3D). In addition, in the 
patients who survived, the above-mentioned parameters 
were measured 3 mo after LDLT. All protocols used in 
the present study were approved by our institutional 
review board (approved No. C-297) and were based 
on the ethical guidelines of the Helsinki Declaration. 
Informed consent was obtained from all patients before 
enrollment. For individually, temporally, and repeatedly 
measured data, differences in the changes over time 
after LDLT between the two groups were analyzed by 
repeated-measures analysis of variance. Differences in 
unpaired discontinuous data between the two groups were 
analyzed by the Mann-Whitney U test. Survival rates 
were calculated by the Kaplan-Meier method, and the 
log-rank test was used for between-group comparisons 
of recipient survival. Values of P < 0.05 were considered 
statistically significant.
There were no significant differences in the absolute 
CO (Figure 4A), CI, BV (Figure 4B), CBV (Figure 4C), 
or MAP between the two groups, although the absolute 
HR showed differences (Figure 4D). There were also 
no significant differences in the absolute TPR, which 
closely reflected vascular alterations (Figure 5A). The 
balance between CO and BV (i.e., CO/BV) clearly showed 
significant differences between the groups (Figure 5B). 
There were significant differences in the PVF velocity 
(Figure 6A) and PVF volume (Figure 6B) between the 
groups, although the variables for hepatic arterial flow 
showed no differences. There were also significant dif-
ferences in the ICG elimination constant (kICG), which 
mainly reflects PVF in the early postoperative period[1,2,32]. 
The CBV reflects the greater circulatory system, 
and some researchers have suggested that this greater 
circulation in patients with LC may be slightly lower than 
that in healthy individuals[33], although the total BV is 
significantly higher in patients with LC. Our data also 
demonstrated no remarkable differences in the greater 
circulation itself between patients with LC and healthy 
individuals.
The absolute CO, BV, CBV, HR, TPR, and kICG in 
LT recipients who were still alive 3 mo after LDLT are 
summarized in Figure 7. Our data support the previous 
opinion that cirrhotic vascular alterations still remain 
long after LT[29,30].
OPTIMAL HEMODYNAMIC STATE IN 
RECIPIENTS WITH LC AFTER LT
As described above, recipients with LC exhibit a persistent 
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Figure 3  Pre-transplant factors and post-transplant course. A: Child-Pugh score; B: MELD score; C: Duration of ICU stay; D: Survival rate. ICU: Intensive care 
unit; LT: Liver transplantation; MELD: Model for end-stage liver disease; NS: Not significant.
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Stability of characteristic systemic hyperdynamic para-
meters after LT is necessary for successful LT in recipients 
with LC[1,2]. Because recipients with LC exhibit these 
peculiar systemic hyperdynamics even after LT[8,9,11,24-26], 
an accurate real-time evaluation is necessary to ensure 
appropriate intensive management after LT[1,2,15,32]. The 
optimal systemic hemodynamics needed for excellent 
outcomes and the precise parameters for the most 
appropriate clinical strategy remain unclear[1,32] because 
the absolute values themselves, such as CO, CI, BV, 
CBV, and MAP, are not necessarily satisfactory for the 
detection of the subtle instabilities of these patients’ 
peculiar hyperdynamic state[1,2].
CONCEPT OF CO STANDARDIZATION 
AGAINST BV
Several investigators have used CO and/or CI to assess 
hemodynamics after LT[8,11,12,25]. Use of the CI, an index 
that concisely standardizes CO against the body surface 
area, has been popularized as a standardized CO value 
for better assessment. Similar to CO, BV is also one of 
the most important factors affecting cardiac preload[14,34]. 
Intrinsically, preload is a concept that represents the 
blood load in the left ventricle and considers the left 
ventricle as the center of blood ejection[1,15]. Therefore, 
the left ventricular end-diastolic volume becomes a 
quantitative parameter[1,15]. The preload usually replaces 
actual clinical assessment with parameters represent-
ing pressures such as the pulmonary capillary wedge 
pressure and central venous pressure[14,35]. The central 
venous pressure can be a useful indicator of the filling 
status of the right ventricle; it is especially useful when 
followed over time and combined with a measurement 
of cardiac output[36]. Pressure-expressing parameters 
including the pulmonary capillary wedge pressure and 
central venous pressure are mainly provided by the CO 
and BV[35]. Therefore, although pressure-expressing para-
meters do not necessarily reflect the left ventricular end-
diastolic volume[14,15], pressure-expressing parameters 
that reduce the precision of assessment of the systemic 
hemodynamics have been paradoxically used to judge 
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Figure 4  Actual changes in systemic hemodynamic parameters. A: CO; B: BV; C: CBV; D: HR. Gray zones represent normal ranges. BV: Blood volume; CBV: 
Central blood volume; CO: Cardiac output; HR: Heart rate; LT: Liver transplantation; NS: Not significant.
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distinct factors that represent the amount of BV and 
strength of CO clinically because BV monitoring has been 
impossible in the past[14,15]. It is necessary to standardize 
CO against BV, but not against the body surface area, 
for precise evaluation of preload[1]. Currently, the PDD 
guarantees noninvasive vigilance of the balance between 
CO and BV as an index for precise assessment of the 
systemic hemodynamic state[1,15]. The CO/BV ratio is a 
reliable indicator of the optimal systemic hemodynamic 
state after LT[1,2]. Preload focuses on the balance between 
CO and BV, and cirrhotic systemic hemodynamics are 
characterized by a high CO and large BV[6-9,12,24-26,35]. Real-
time assessment of CO and BV by making the best use 
of noninvasive PDD may become an effective strategy 
for evaluating the systemic hemodynamic state in LT 
recipients with LC.
IMPACT OF SYSTEMIC HEMODYNAMIC 
STATE ON PVF AFTER LT
Postoperatively, LT recipients with LC show a clear ten-
dency toward PVF overflow compared with healthy in-
dividuals[2]. The systemic hemodynamics impact the local 
graft circulation after LT[1,2], and even a subtle systemic 
hyperdynamic disorder strongly affects the splanchnic 
circulation. An imbalance between CO and BV decreases 
the PVF, which results in critical outcomes[1,2]. In brief, 
an optimal balance between CO and BV guarantees 
adequate PVF after LT[1,2]. Interestingly, subtle disorders 
in the optimal systemic hyperdynamic state more easily 
influence the PVF than the hepatic arterial flow[2]. Va-
scular alterations secondary to PH develop in the vessels 
that originally flow into the portal vein under normal 
PVP. Such alterations are one cause of a large BV[2]. The 
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Figure 5  Actual changes in systemic hemodynamic parameters. A: TPR; B: 
CO/BV. Gray zones represent normal ranges. BV: Blood volume; CO: Cardiac 
output; LT: Liver transplantation; NS: Not significant; TPR: Total peripheral 
resistance.
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Figure 6  Actual changes in portal venous flow and indocyanine green 
elimination constant. A: PVF velocity; B: PVF volume; C: kICG. Gray zones 
represent normal ranges. ICG: Indocyanine green; kICG: Indocyanine green 
elimination constant; LT: Liver transplantation; PVF: Portal venous flow.
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intestine and spleen become a pool for the large BV[37]. 
Postoperative imbalance between the greater CO and 
larger BV cause stagnation of the tributary blood flow in 
the dilated veins and collateral pathways, resulting in a 
decrease in PVF[2]. Transplant physicians should never 
forget that the systemic hyperdynamic state persists in 
recipients with LC even after LT[1,2,8,11,24-26] and that this 
peculiar systemic hemodynamic stability is indispensable 
for adequate PVF after LT[1,2]. 
Actual images of Doppler ultrasound in cases with-
out stability of systemic hemodynamic state (i.e., an 
imbalance of CO and BV in the lower TPR) are shown 
in Figure 8. The PVF should be detected as a stationary 
wave. However, in a case of unstable systemic hyper-
dynamic state, the waveform of PVF may seem to be 
undulant. Moreover, HA waveform may blend into the 
background of a decreased PVF.
INTENTIONAL MODULATION OF PVP 
DURING LDLT
Partial liver grafting is inevitable in the LDLT setting, 
and the allograft size from the live donor is therefore 
insufficient. Intentional modulation of the PVP to ≤ 15 
mmHg is a simple and sure strategy during LDLT[38-42]. 
Detailed surgical procedures for intentional modulation of 
PVP have been described elsewhere[40,41]. Paradoxically, 
the acceptable minimum GRWR of < 0.7 is possible at 
graft selection[40] because intentional PVP modulation 
during LDLT will prevent small-for-size syndrome after 
LDLT[38-42]. Although intentional PVP control seems to 
overcome an GRWR of < 0.7, these grafts still cause 
critical problems when evaluated retrospectively[40]. 
Selection of a graft with an GRWR of ≥ 0.8 and estab-
lishment of a target PVP of ≤ 15 mmHg during LDLT are 
considered keys for successful LDLT[40]. Optimal PVF is 
required for successful LDLT[2,43]. Ligation of collaterals 
and shunts often require an advanced surgical tech-
nique because these vessels are always abnormal[41,42]. 
However, intentional setting of the PVF during LDLT is 
effective not only to trigger liver regeneration after LT, but 
also to prevent steal of PVF after LDLT.
STRATEGIC VALUE OF ICG KINETICS 
DURING LT
ICG is widely used for analysis of liver functions because 
it is exclusively eliminated by the liver without involve-
ment of the enterohepatic circulation and does not 
accumulate in the body[44]. Asialoglycoprotein receptors 
on hepatocytes are characteristic of functional liver cells[45], 
and liver scintigraphy using 99mTc-galactosyl human serum 
albumin has been used as a reliable method of assess-
ment of the hepatic functional reserve in hepatectomy 
and graft parenchymal function after LT[46-48]. There is 
a correlation between ICG clearance and the hepatic 
uptake ratio assayed by liver scintigraphy[45,46].
ICG kinetics reflect the functional hepatocytes (cell 
volume) and effective PVF (clearance)[31,49-52], and PVF is a 
major determinant of kICG in the normal liver[32,34,49,51,53]. 
The PVF has a large influence on liver regeneration after 
LT[32,43], and reversible damage to hepatocytes begins 
immediately after graft recirculation[32,38,39,43]. Some 
researchers have focused on ICG kinetics as a liver 
function test after LT[31,32], and kICG values can predict 
clinical outcomes in the early postoperative period after 
LDLT by closely reflecting the influence of systemic 
dynamics on the splanchnic circulation[32].
Hepatocytes are well preserved in LDLT because 
the cold storage time (CIT) is shorter. The kICG reflects 
the optimum PVF value during LT and in the early post-
operative period[41,42]. Hence, a division by graft weight 
is a simple resolution to ensure that the kICG reflects 
only the PVF based on the advantage of well-preserved 
hepatocytes during LDLT[41,42]. Intentional PVP modulation 
based on real-time PVP monitoring and the confirmation 
of an optimal kICG/graft weight value reflecting the 
















































































Figure 7  Systemic hemodynamic parameters 3 mo after liver transplantation. A-F: CO, BV, CBV, HR, TPR, and kICG in patients who survived are shown. Gray 
zones represent normal ranges. BV: Blood volume; CBV: Central blood volume; CO: Cardiac output; HR: Heart rate; ICG: Indocyanine green; kICG: Indocyanine 
green elimination constant; LT: Liver transplantation; TPR: Total peripheral resistance.
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during LDLT[41,42]. Actually, in some cases, the kICG 
value did not change even with intentional controls to 
decrease or increase the PVP[41]. In other cases, the 
kICG values improved with an increased PVP by ligation 
of portosystemic collaterals or a decrease in the PVP by 
splenectomy[41]. Thus, these factors seemed to show 
some discrepancies in some cases[41,42]. The relationship 
between PVP and PVF remains unclear[42]. The usefulness 
of ICG kinetics during LT was first described in 2012[41]. 
Simultaneous fulfillment of a final PVP of ≤ 15 mmHg 
and a final kICG of > 4 × 10−4/g × the graft weight (g) 
is a sure strategy for achieving the optimal PVF during 
LDLT[41]. Thereafter, the cut-off level of the final kICG/
graft weight was demonstrated as 3.1175 × 10-4/g[42]. 
The final kICG/graft weight during LT has potential as an 
accurate parameter for the optimal PVF and as a reliable 
predictor of the postoperative course and outcome after 
LT[41,42]. 
KEY POINTS AND UNEXPECTED 
PITFALLS IN PERIOPERATIVE 
MANAGEMENT OF LT RECIPIENTS WITH 
ADVANCED LC
Liver allografts are at risk of problems such as cold 
ischemia/warm reperfusion injury, acute rejection, dis-
ease recurrence and hepatic blood flow disorders[32]. 
Transplant physicians should consider many factors sim-
ultaneously.
Eventration of the diaphragm because of intract-
able ascites, or easily broken ribs, often disrupts ven-
tilation[54]. Vascular alteration due to long-term PH 
causes endothelial injury and permeant breakdown and 
subsequently results in large amounts of ascites, pleural 
effusion, and gastric fluid[55]. The electrolyte composition 
of these third-space fluids may not be similar to that of 
the extracellular fluid, and the electrolyte composition of 
third-space fluids should be checked once if the quantity 
is large[56]. Replenishment for third-space loss should be 
performed using not Ringer’s solution but bicarbonated 
Ringer’s solution[57-59] if the electrolyte composition is 
similar to that of the extracellular fluid and if the third-
space loss is quantitatively large.
Careless management techniques, such as rapid 
increases or decreases of transfusions and medications, 
are detrimental[60,61]. Effects of increases or decreases of 
transfusions are usually reflected on a day-to-day basis 
because of the peculiar cirrhotic hemodynamics[55,60,61], 
and a roller-coaster management technique that repeat-
edly changes within a single day will trigger poor clinical 
courses with unexpected complications[60,61]. All transfusion 
management plans should be handled with great caution, 
and transplant physicians should very carefully evaluate 
the effects of increases or decreases of transfusions[60-62]. A 
response time lag due to endothelial injury and permeant 
breakdown should be considered in LC recipients with 
long-term PH[63-65]. Adequate hydration is also required; 
dehydration should be avoided because of these patients’ 
peculiar hemodynamics. Even temporal dehydration 
causes unexpected thrombosis, renal failure, and impaired 
drug metabolism[60-62]. Plans to stay within stable systemic 
hemodynamics (e.g., noradrenaline to maintain CO and 
well-hydration with human atrial natriuretic peptide) 
should be considered. Tachycardia may lower the CO. 
A lower CO that is insufficient to circulate the larger BV 
decreases the PVF, and a lower PVF results in a poor 
outcome. As described above, vascular alterations cause 
the large BV in these patients[2], and the intestine and 
spleen become pools for the large BV[37]. Even a subtle 
imbalance between the greater CO and larger BV induced 
by roller-coaster management triggers a decrease in the 
PVF[2,60,61]. 
Long-term PH causes splanchnic congestion and in-
tractable ascites. Splanchnic congestion results in break-
down of the enteric barrier[66], and portal venous gas and/
or abdominal compartment syndrome may be temporally 
observed[66-68]. Induction of drugs with fibrolytic activity (not 
heparin, but urokinase and warfarin) should be initiated 
without hesitation based on the endothelial damage in 
patients with LC, although heparin induction may be 
effective from the viewpoint of thromboprophylaxis[69]. 
Notably, long-term biliary drainage may cause coagu-
lopathy due to impaired absorption of vitamins[70]. Massive 










Figure 8  Decreased portal venous flow due to unstable systemic hyper­
dynamic state (A and B). Even a subtle instability of systemic hyperdynamic 
state (i.e., an imbalance of CO and BV in the lower TPR) results in a decreased 
PVF. During the PVF measurement by Doppler ultrasound, HA waveform (Red 
line) blends into the background of a decreased PVF (purple lines). BV: Blood 
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permeant breakdown, and systemic arterial pressure 
may be effected even by body motion[63-65]. Diuretics 
(e.g., furosemide and potassium-conserving diuretics) 
and a water-clearance mediator (e.g., tolvaptan) are 
available[71]. Hemodynamic disorders such as hepatic 
venous obstruction and portal thrombosis may develop if 
no response is observed after diuretic induction[72].
The most frequent cause of morbidity and mortality 
after LT is not immunological rejection but infection-
related complications[73-75]. Some infections are usually 
intractable in patients with LC, including bacterial cholan-
gitis[76], spontaneous bacterial peritonitis[77], spontaneous 
bacterial empyema[78], viral infection[79], aspergillosis[80], 
and Pneumocystis jirovecii pneumonia (formerly known 
as Pneumocystis carinii pneumonia)[81]. Because the 
postoperative risk of complications is associated with the 
pretransplant conditions[82,83], these infections should 
be ruled-out and/or treated beforehand. Even a subtle 
infection will trigger severe complications after LT[73-75,83,84]. 
Evaluation of LT candidates should be carefully per-
formed[83,85,86]; pretransplant infections may greatly 
impair the clinical course and outcomes after LT[83,87,88]. 
Transplant physicians should never forget that intentional 
pretransplant control of infections, including bacterial, 
viral, and fungal infections, has a large influence on 
allograft function and survival[89,90]. Uncontrolled infections 
will have catastrophic effects[83,87,88], and any infections 
should therefore be treated before LT.
Glycemic control also has an influence on the clinical 
course after LT[91]. Good glycolytic activity and glycemic 
control in the perioperative period will help to ensure 
adequate liver regeneration[92,93].
DISTINCTION BETWEEN 
HEPATOPULMONARY SYNDROME AND 
PORTOPULMONARY HYPERTENSION
Hepatopulmonary syndrome (HPS) and portopulmonary 
hypertension (PPHTN) are cardiopulmonary complica-
tions[3,94-97] that are frequently seen in patients with 
LC[54,94-98]. Both conditions result from a lack of hepatic 
clearance of vasoactive substances produced in the 
splanchnic territory[95]. These substances mainly cause 
subsequent pulmonary vascular remodeling. In previous 
studies, some degree of vasoconstriction in patients 
with PPHTN resulted in pulmonary arterial hypertension 
(PAH) and right ventricular dysfunction[54,98]. The current 
definition of PPHTN includes secondary PAH due to 
portosystemic shunts[98]. In patients with HPS, these 
vasoactive mediators cause intrapulmonary shunts with 
hypoxemia[97]. The HPS is accompanied by abnormal 
pulmonary gas exchange and evidence of intrapul-
monary vascular dilatation that results in a right-to-left 
intrapulmonary shunt[98]. These entities are both clinically 
and pathophysiologically distinct[3,94,95], and PPHTN and 
HPS should be considered as different pathological 
states[98]. HPS is characterized by abnormal pulmonary 
vasodilation and right-to-left shunting that result in gas 
exchange abnormalities[3,54,94,95,97,98], whereas PPHTN is 
caused by pulmonary artery vasoconstriction that leads 
to hemodynamic failure[3,94-96]. Both HPS and PPHTN 
are associated with significantly increased morbidity 
and mortality[3,94,95,97], although these patients are 
commonly asymptomatic. All candidates for LT should 
be actively screened for the presence of these two com-
plications[54,94,95,97,98].
Although LT results in the disappearance of HPS 
within 1 year[95,99], the effect of LT on PPHTN is highly 
unpredictable[54,95,98-101]. PPHTN with PAH has historically 
been a contraindication for LT[54,98-100]. However, the 
diagnosis and treatment of PPHTN have advanced during 
the past two decades[54]. Assessment of patients’ pre-
operative reactivity and response to pharmacological 
therapies for moderate-to-severe PPHTN is important to 
ensure excellent survival rates after LT[102]. Prostaglandin 
I2 has drastically improved outcomes[103] and is currently 
considered a key drug in the control of PPHTN[103]. Modern 
strategies in managing HPS and PPHTN rely on a thorough 
screening and grading of the disease severity to tailor 
the appropriate therapy and select only the patients 
who will benefit from LT[54,95,97-101]. Hemodynamic and 
respiratory modifications in the perioperative period must 
be avoided through continuation of the preoperatively 
initiated drugs, appropriate intraoperative monitoring, and 
proper hemodynamic and respiratory therapies[54,95,98,99]. 
The most reliable monitoring factor for PPHTN with PAH 
during the perioperative period is the mean pulmonary 
arterial pressure[54,98], though supplemental oxygen and 
monitoring of oxygen saturation during the perioperative 
period are adequate for monitoring of HPS[97,104,105].
COAGULOPATHY AND ENDOTHELIAL 
INJURY
The systemic hyperdynamic state causes vessel dilation 
and collateral development, and the venous endothelium 
becomes damaged[4,65]. An intact endothelial barrier is 
important, especially in critical situations such as sepsis 
and thrombotic microangiopathy[106,107]. High mobility 
group box 1 (HMGB1) is an evolutionarily conversed 
nuclear protein that is passively released by almost all 
cells during cellular necrosis and is actively secreted 
from activated macrophages, monocytes, and endothelial 
cells[108]. Once secreted into the extracellular space, 
HMGB1 serves as a dangerous signal that stimulates 
inflammatory reactions[108]. Thrombomodulin (TM) is 
an endothelial anticoagulant cofactor that promotes 
thrombin-mediated formation of activated protein C[109]. 
TM plays an anti-inflammatory role through inactivation 
of HMGB1[109,110]. Recombinant human soluble TM (rTM) 
has recently become available[111], and this novel drug 
is effective for sepsis[110]. Thrombotic microangiopathy 
and a positive lymphoid cross-match combination will 
result in poor outcomes after LT, especially in adult 
recipients[112,113]. Intrahepatic and vascular conditions 
pathophysiologically overlap. Pathophysiologically, rTM 
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is effective for sepsis and thrombotic microangiopathy in 
LT recipients[107,111], although there are no reports of its 
usefulness for ABO incompatibility in patients undergoing 
LT. Vascular alterations including endothelial injury still 
remain even after LT. Based on our experience, the dose 
of rTM should be reduced to two-thirds of the regular 
dose in LT recipients with LC, although one-half of the 
regular dose loses any effects. 
MEDICAL ECONOMY
Insurance systems are different in each country[114,115], 
and every country has its own limitations of medical 
resources[116]. Hence, transplant physicians should always 
consider a cost-benefit analysis if they want to continue 
an effective LT program[116,117]. Dialysis treatment, plasma 
exchange, blood derivatives, and direct-acting antivirals 
are very expensive[62,118,119]. Notably, attempts to perform 
blood transfusion and infusion of fraction products are ill-
advised because they are very detrimental to the medical 
economy[62,116,117,119]. A shorter intensive care unit (ICU) 
stay has benefits for patients[120], although expensive 
and intensive care during the ICU stay is needed for 
post-transplant management. Longer hospital stay 
impairs quality of life and spoil social status after hospital 
discharge[121,122].
DISCUSSION
It is necessary to standardize CO against BV for precise 
evaluation of preload[1]. Considering that cirrhotic hyper-
dynamics are consolidated in patients with a large BV 
and high CO under a low TPR[3,6,8-10] and that the concept 
of preload is focused on the balance between CO and 
BV[35], we can now use the new concept of the CO/BV 
ratio by making the best use of available devices that 
can noninvasively measure BV[1,2,15]. The PDD guarantees 
noninvasive vigilance of the balance between CO and 
BV as an index for precise assessment of the systemic 
hemodynamic state in LT recipients with LC[1]. The CO/
BV ratio expresses the CO per min corresponding to 
a fraction of the BV, which represents how the heart 
efficiently ejects the BV that should be circulated[1,2]. 
Interestingly, previous studies revealed no differences in 
the CO/BV among recipients with LC, recipients without 
LC, and healthy individuals[1,2]. This variable has potential 
as a reliable clinical marker after LT. Subtle instabilities 
that do not appear when comparing absolute values 
themselves are simply indicated by the balance between 
CO and BV[1,2]. It seems reasonable that tachycardia 
resulted in a lower CO in recipients with poor outcomes 
(Figure 4D) and that the decreased CO could not circu-
late the large BV in these recipients (Figure 5B).
In LDLT, the CIT is short and the hepatocytes are well 
preserved[41]. Therefore, division by the graft weight is a 
simple method that allows the kICG to reflect only the 
PVF, by taking advantage of the shorter CIT in LDLT[41]. 
Strategic values in ICG kinetics are used to set the 
optimal PVF during LDLT and to evaluate the optimal 
systemic hemodynamics after LT[1,2,32,41,42]. ICG kinetics 
reflects the functional hepatocyte volume and effective 
PVF[31,49-52]. Advanced selection criteria of a graft with 
an GRWR of ≥ 0.6 and establishment of a target PVP 
of ≤ 15 mmHg during LDLT are currently documented 
for successful LDLT[123-126]. This defiant set-up with 
lower GRWR has advantages for donor pool and safety, 
although these grafts may cause critical problems[40]. 
ICG kinetics is useful to set-up of adequate PVF during 
LDLT with lower GRWR. Conversely, in deceased-donor 
LT, although PVF is a major determinant of kICG in the 
normal liver[32,34,49,51,53], the kICG value may be affected 
by damaged hepatocytes due to the longer CIT. The 
decreased kICG may not indicate only an inadequate 
PVF in deceased-donor LT because ICG kinetics is dually 
factorial.
CONCLUSION
LT recipients with LC exhibit peculiar hemodynamics (i.e., 
systemic hyperdynamic syndrome and PH). Vascular 
alterations do not easily disappear despite restora-
tions of PH and liver function in recipients with LC, and 
PVF impacts liver regeneration after LT[43]. Stability of 
characteristic systemic hyperdynamics is indispensable 
for adequate PVF and successful LT[1,2]. Even a subtle 
disorder of the systemic hyperdynamics dictates PVF[1,2]. 
ICG kinetics is useful to set an adequate PVF during 
LDLT and evaluate the optimal systemic hemodynamics 
after LT[1,2,32,41,42]. Perioperative management has a large 
influence on the postoperative course and outcome. Tran-
splant physicians should fully understand the peculiarities 
of cirrhotic hemodynamics. We hope that this review will 
be informative for transplant physicians.
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